Biotherapeutic agents: A neglected modality for the treatment and prevention of selected intestinal and vaginal infections

JAMA

Volumn 275, Issue 11, 1996, Pages 870-876

  Elmer, Gary W ^a   Surawicz, Christina M ^b   McFarland, Lynne V ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DIARRHEA; ENTEROCOCCUS FAECALIS; HUMAN; INTESTINE INFECTION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BIFIDUS; LACTOBACILLUS CASEI; MICROORGANISM; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS;

EID: 0029919917     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.11.870     Document Type: Review

References (81)

1. Fuller R. Probiotics in human medicine. Gut. 1991;32:439-442.
2. McFarland LV, Elmer GW. Biotherapeutic agents: past, present and future. Microecology Ther. 1995;23:46-73.
3. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573-581.
4. McFarland LV. Diarrhea acquired in the hospital. In: Giannella RA, ed. Acute Infectious Diarrhea. Philadelphia, Pa: WB Sauaders Co; 1993:563-577.
5. Zaidi N, Ponce de Leon S, Ortiz RM, et al. Hospital-aquired diarrhea in adults: a prospective case-controlled study in Mexico. Infect Control Hosp Epidemiol. 1991;12:349-355.
6. Lima NL, Guerrant RL, Kaiser DL, Garmanson T, Farr BM. A retrospective cohort study of nosoeomial diarrhea as a risk factor for nosocomial infection. J Infect Dis. 1990;161:948-952.
7. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA. 1993;269:71-75.
8. Adam J, Barret A, Barret-Bellet C, et al. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée: étude multicentrique par 25 médecins de 388 cas. Gazette Med France. 1977;84:2072-2078.
9. Surawicz CM, Elmer GW, Speelman P, MeFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastronterology. 1989;96:981-988.
10. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared to placebo. Am J Gastroenterol. 1995;90:439-448.
11. Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a Lactobacillus preparation. Am J Hosp Pharm. 1979;36:754-757.
12. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP. 1990;24:382-384.
13. Clements ML, Levine MM, Black RE, et al. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrob Agents Chemother. 1981;20:104-108.
14. de Dios-Pozo-Alano J, Warram JH, Gomez RG, Cavazos MG. Effect of a Lactobacilli preparation on traveler's diarrhea: a randomized, double blind clinical trial. Gastroenterology. 1978;74:829-830.
15. Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med. 1990;22:57-59.
16. Colombel JF, Cortot A, Neut C, Romond C. Yoghurt with Bifidobacterium longum reduces erythromycm-induced gastrointestinal effects. Lancet. 1987;2:43.
17. Orrhage K, Brismar B, Nord CE. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Microb Ecology Health Disease. 1994;7:17-25.
18. Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res. 1989;17:333-338.
19. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet. 1994;344:1046-1049.
20. Oksanen PJ, Salminen S. Saxelin M, et al. Prevention of travelers' diarrhoea by Lactobacillus GG. Ann Med. 1990;22:53-56.
21. Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prophylaxe der Reisediarrhöe mit Saccharomyces boulardii. Fortschr Med. 1993;111:153-156.
22. McFarland LV. The epidemiology of Clostridium difficile infections. Gastroenterol Int. 1991; 4:82-85.
23. Bowden TA, Mansberger AR, Lykins LE. Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis. Am Surg. 1982;4:178-183.
24. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet. 1983:2:845.
25. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
26. Gorbach SL, Chang T-W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987;2:1519.
27. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr. 1995;21:224-226.
28. Surawicz CM, McFarland LV, Elmer GW, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989;84:1285-1287.
29. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-1918.
30. Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis, part 1. Am J Hasp Pharm. 1994;51:1771-1781.
31. Saint-Marc T, Rossello-Prats L, Touraine JL. Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA. Ann Med Interne (Paris). 1991;142:64-65.
32. Elmer GW, Moyer KA, Vega R, et al. Evaluation of Saccharomyces boulardii for patients with HIV-related diarrhea and healthy volunteers receiving antifungals. Microecology Ther. In press.
33. Kotler DP. Gastrointestinal manifestations of human immunodeficiency virus infection. Adv Intern Med. 1995;40:197-242.
34. Belitsos PC, Greenson JK, Yardley JH, Sisler JR, Bartlett JG. Association of gastric hypoacidity with opportunistic infections in patients with AIDS. J Infect Dis. 1992;166:277-284.
35. Chapoy P. Treatment of acute infantile diarrhea; controlled trial of Saccharomyces boulardii. Ann Pediatr (Paris). 1985;32:561-563.
36. Cetina-Sauri G, Basto GS. Evaluación terapéutica de Saccharomyces boulardii en nin̄os con diarrea aguda. Tribuna Med. 1989;56:111-115.
37. Hochter W, Chase D, Hagenhoff G. Saccharomyces boulardii bei akuter Erwachsenendiarrhoe: Wirksamkeit und Verträglichkeit der behandlung. Münch Med Wschr. 1990;132:188-192.
38. Mitra AK, Rabbani GH. A double-blind, controlled trial of Bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio chalerae and enterotoxigenic Escherichia coli. Gastroenterology. 1990;99:1149-1152.
39. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991;88:90-97.
40. Reuman PD, Duckworth DH, Smith KL, Kagan R, Bucciarelli RL, Ayoub EM. Lack of effect of Lactobacillus GG on gastrointestinal bacterial colonization in premature infants. Pediatr Infect Dis J. 1986;5:663-668.
41. Millar MR, Bacon C, Smith SL, Hall MA. Enteral feeding of premature infants with Lactobacillus GG. Arch Dis Child. 1993;69:483-487.
42. Touhami M, Boudraa G, Mary JY, Soltana R, Desjeux JF. Clinical consequences of replacing milk with yogurt in persistent infantile diarrhea. Ann Pediatr (Paris). 1992;39:79-86.
43. Larsen B. Vaginal flora in health and disease. Clin Obstet Gynecol. 1993;36:107-121.
44. Reid G, Bruce AW, McGroarty JA, Cheng K-J, Costerton JW. Is there a role for Lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev. 1990;3:335-344.
45. 2-producing lactobacilli and bacterial vaginosis in pregnant women. Clin Infect Dis. 1993;16(suppl 4):S273-S281.
46. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med. 1992;116:353-357.
47. Hilton E, Rindos P, Isenberg HD. Lactobacillus GG vaginal suppositories and vaginitis. J Clin Microbiol. 1995;33:1433.
48. McGroarty JA. Probiotic use of Lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol. 1993;6:251-264.
49. Hughes VL, Hillier SL. Microbiologic characteristics of Lactobacillus products used for colonization of the vagina. Obstet Gynecol. 1990;75:244-248.
50. Reid G, Bruce AW, Taylor M. Influence of three-day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther. 1992;14:11-16.
51. Silva M, Jacobus NV, Deneke C, Gorbach SL. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother. 1987;31: 1231-1233.
52. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev. 1993;12:221-238.
53. Axelsson LT, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecology Health Dis. 1989;2:131-136.
54. Ramare F, Nicoli J, Dabard J, et al. Trypsin-dependent production of an antibacterial substance by a human Peptostreptococcus strain in gnotobiotic rats and in vitro. Appl Environ Microbiol. 1993;59:2876-2883.
55. Wilson KH, Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun. 1988;56:2610-2614.
56. Michelich VJ, Nuñez-Montiel O, Sehuster GS. Thompson F, Dowell VR. Diet as a coadjuvant for development of antibiotic-associated diarrhea in hamsters. Lab Anim Sci. 1981;31:259-262.
57. Mahe S, Corthier G, Dubos F. Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice. Infect Immun. 1987;55:1801-1805.
58. Blomberg L, Henriiksson A, Conway PL. Inhibition of adhesion of Escherichia coli K88 to piglet ileal mucus by Lactobacillus spp. Appl Environ Microbiol. 1993;59:34-39.
59. Coconnier MH, Bernet MF, Kerneis S, Chauviere G, Fourniat J, Servin AL. Inhibition of adhesion on enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion. FEMS Microbiol Lett. 1993;110:299-306.
60. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994; 35:483-189.
61. Rigothier MC, Maccano J, Gayral P. Inhibitory activity of saceharomyces yeasts on the adhesion of Entamoeba histolytica, trophozoites to human erythrocytes in vitro. Parasitol Res. 1994;80:10-15.
62. Rigothier MC, Macario J, Vuong PN, Gayral P. Effets des levures Saccharomyces boulardii sur les trophozoites d'Entamoeba histolytica in vitro et dans l'amibiase caecale de jeune rat. Ann Parasitol Hum Comp. 1990;65:51-60.
63. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium. difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108-1115.
64. Vidon N, Huchet B, Rambaud JC. Influence de Saccharomyces boulardii sur la secretion jejunale induite chez le rat par la toxine cholerique. Gastroenterol Clin Biol 1986;10:13-16.
65. Czerucka D, Roux I, Rampai P. Saccharomyces boulardii inhibits secretegogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology. 1994;106:65-72.
66. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, de Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986;20:192-196.
67. Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990;35:251-256.
68. Buts JP, de Keyser N, de Raedemaekier L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res. 1934;36:522-527.
69. Ducluzeau R, Bensaada M. Effet comparé de l'administration unique ou en continu de Saccharomyces boulardii sur l'établissement de diverses souches de candida dans le tractus digestif de souris gnotoaxéniques. Ann Microbiol (Paris). 1982;133: 491-501.
70. Caetano JA, Parames MT, Babo MJ, et al. Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol. 1986;8:245-259.
71. Perdigon G, De Macias MEN, Alvarez S, Oliver G, DeRuiz Holgada AAP. Effect of periorally administered lactobacilli on macrophage activation in mice. Infect Immun. 1986;3:404-410.
72. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992; 32:141-144.
73. Blatz R, Schroder R, Linde K. The influence of oral application of viable or inactivated Escherichia coli on the intestinal ecology of conventional mice. Microecology Ther. 1987;17:191-196.
74. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992;37:121-128.
75. Lidbeck A, Gustafsson J-A, Nord CE. Impact of Lactobacilius acidophilus supplements on the human oropharyngeal and intestinal microflora. Scand J Infect Dis. 1987;19:531-537.
76. Klein SM, Eimer GW, MeFarland LV, Surawiez CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res. 1993;10: 1615-1619.
77. Bouhnik Y, Pochart P, Marteau P, Arlet G, Goderel I. Rambaud JC. Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterology. 1992;102:875-878.
78. Mynott TL, Chandler DS, Luke RK. Efficacy of enteric-coated protease in preventing attachment of enterotoxigenic Escherichia coli and diarrheal disease in the RITARD model. Infect Immun. 1991; 59:3708-3714.
79. Pletincx M, Legein J, Vandenplas Y, Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr. 1995;21:113-115.
80. McConnell MA, Mercer AA, Tannock GW. Transfer of plasmid pAMβ1 between members of the normal microflora inhabiting the murine digestive tract and modification of the plasmid in a Lactobacillus reuteri host. Microb Ecology Health Disease. 1991;4:343-355.
81. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces baulardii in man and rat. Biopharm Drug Dispos. 1989;10:353-364.